Twenty-five to thirty percent of potential U.S. Tobi candidates, or 5,000-5,500 cystic fibrosis patients, currently take the drug, PathoGenesis CEO Wilbur Ganz tells analysts. The company hopes to reach 7,000 patients, or 38% of the 18,000 potential U.S. patients, by year-end. Twenty-four sales reps currently promote the cystic fibrosis treatment, approved in December 22, 1997. Ongoing Phase II trials are evaluating Tobi in bronchiectasis and tuberculosis, with an Phase I/II trial in long-term ventilator patients expected to commence in early 1999. Company expects to file IND for its second aerosolized antibiotic, PA-1420 (polymyxin E1) in 1999
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth